Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
2(18%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_4
2
18%
Ph phase_1
2
18%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(4)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Active, not recruiting2
Not yet recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (50.0%)
Phase 42 (50.0%)

Trials by Status

withdrawn19%
completed655%
active_not_recruiting218%
not_yet_recruiting218%

Recent Activity

2 active trials
Showing 5 of 11
active_not_recruitingphase_4

Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)

NCT07547878
completed

Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

NCT05262764
active_not_recruiting

Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

NCT06527846
not_yet_recruiting

Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction

NCT07044700
completed

JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

NCT06287073
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07547878Phase 4

Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)

Active Not Recruiting
NCT05262764

Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Completed
NCT06527846

Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Active Not Recruiting
NCT07044700

Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction

Not Yet Recruiting
NCT06287073

JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

Completed
NCT07035457Phase 1

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together

Completed
NCT05236673

Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

Completed
NCT06280976Phase 4

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

Withdrawn
NCT06308679Phase 1

A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Not Yet Recruiting
NCT02367131

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Completed
NCT02489942

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11